Raymond James Initiates Coverage On BridgeBio Oncology with Outperform Rating, Announces Price Target of $24
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
Raymond James analyst Sean McCutcheon initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $24.
Raymond James analyst Sean McCutcheon initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $24.